Van de Veire, S; Stalmans, I; Heindryckx, F; Oura, H; Tijeras-Raballand, A; Schmidt, T; ... Carmeliet, P; + view all Van de Veire, S; Stalmans, I; Heindryckx, F; Oura, H; Tijeras-Raballand, A; Schmidt, T; Loges, S; Albrecht, I; Jonckx, B; Vinckier, S; Van Steenkiste, C; Tugues, S; Rolny, C; De Mol, M; Dettori, D; Hainaud, P; Coenegrachts, L; Contreres, JO; Van Bergen, T; Cuervo, H; Xiao, WH; Le Henaff, C; Buysschaert, I; Masouleh, BK; Geerts, A; Schomber, T; Bonnin, P; Lambert, V; Haustraete, J; Zacchigna, S; Rakic, JM; Jimenez, W; Noel, A; Giacca, M; Colle, I; Foidart, JM; Tobelem, G; Morales-Ruiz, M; Vilar, J; Maxwell, P; Vinores, SA; Carmeliet, G; Dewerchin, M; Claesson-Welsh, L; Dupuy, E; Van Vlierberghe, H; Christofori, G; Mazzone, M; Detmar, M; Collen, D; Carmeliet, P; - view fewer (2010) Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease. CELL , 141 (1) 178 - 190. 10.1016/j.cell.2010.02.039.
Full text not available from this repository.
Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.
|Title:||Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease|
|Keywords:||PLACENTA GROWTH-FACTOR, HEPATOCELLULAR-CARCINOMA, PATHOLOGICAL CONDITIONS, MOUSE MODEL, METASTASIS, ANGIOGENESIS, MICE, PROGRESSION, HYPOXIA, LUNG|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Medical Sciences > Medicine (Division of)|
Archive Staff Only: edit this record